Purpose: To evaluate the efficacy of antibiotic prophylaxis and determine the risk factors of infectious complications after transurethral surgery of the prostate. Materials and Methods: Seven hundred and seventy-two patients who underwent transurethral resection of the prostate (TURP) or holmium laser enucleation of the prostate (HOLEP) were reviewed. Of these, this study enrolled 643 patients without bacteriuria who had not received antibiotics for urinary tract infections for two weeks before surgery. The patients were divided into two groups according to the duration of the antibiotics (Group 1: less than one day, n=396 vs. Group 2: more than one day, n=247). Results: The overall incidence of postoperative infectious complications in 643 patients was 5.0% (32/643). When postoperative infectious complications were compared according to the duration of the antibiotics (Group 1 vs. Group 2), the infectious complications rates were 5.6% (22/396) vs. 4.0% (10/247), respectively (p=0.393). When postoperative infectious complications were compared according to the duration of antibiotics (Group 1 vs. Group 2) in the TURP and HOLEP groups, the infectious complications rates were 6.3% (12/192) vs. 1.0% (1/103) (p=0.035) and 4.9% (10/203) vs. 6.0% (8/134) (p=0.677), respectively. The duration of Foley catheterization was independently associated with infectious complications (p=0.003). Conclusions: The results showed that prolonged postoperative catheterization affects postoperative infectious complications associated with transurethral prostate surgery. Although antibiotics administered for less than one day are effective for antibiotic prophylaxis of transurethral prostate surgery, a longer antibiotic therapy is recommended for TURP.
Purpose: This study examined whether Cystochon® (cranberry extract, chondroitin sulfate, and hyaluronic acid complex) effectively improves the symptoms and problems of interstitial cystitis/bladder pain syndrome (IC/BPS) patients. Materials and Methods: From December 2021 to May 2022, the medical records of IC/BPS patients who visited St. Vincent’s Hospital, Kyung Hee University Medical Center, or Gachon University Gil Medical Center were collected. For the treatment of IC/BPS, the patients were given pentosan polysulfate (PPS) for 12 weeks, with Cystochon® then added and maintained for an additional eight weeks. The OʼLeary–Sant symptom and problem index (Interstitial Cystitis Symptom Index [ICSI], Interstitial Cystitis Problem Index [ICPI]) was used to measure the treatment response. Results: After 12 weeks of PPS treatment, ICSI and ICPI improved in all patients. After adding Cystochon® for eight weeks, the ICSI and ICPI indicators improved further. In the ICSI category, significant improvement in symptoms was confirmed in the total ICSI score, particularly in the Q4 (pain-related) questionnaire after adding Cystochon®. In the ICPI category, significant problem improvement was confirmed in the total ICPI score, particularly in the Q1 (frequent urination) and Q4 (pain-related) questionnaires. Although not statistically significant, the remaining indicators generally tended to improve. Conclusions: The orally administered combination of cranberry extract, chondroitin sulfate, and hyaluronic acid (Cystochon®) may have a clinically positive effect in patients with IC/BPS. Better clinical improvement can be expected when it is added to the PPS treatment, especially in the category of bladder pain.
Citations
Citations to this article as recorded by
Anti-inflammatory effect of sea buckthorn in an HCl-induced cystitis rat model Hyun Suk Yoon, Juyeon Yu, Shinhoon Kang, Hana Yoon Investigative and Clinical Urology.2025; 66(1): 67. CrossRef
Pharmacological Properties of Shionone: Potential Anti-Inflammatory Phytochemical against Different Diseases Varun Jaiswal, Hae-Jeung Lee Molecules.2023; 29(1): 189. CrossRef
Seung-Kwon Choi, Koo Han Yoo, Jeong Woo Lee, Seung Il Jung, Eu Chang Hwang, Joongwon Choi, Woong Bin Kim, Jung Sik Huh, Jin Bong Choi, Yeonjoo Kim, Jae Min Chung, Ju-Hyun Shin, Jae Hung Jung, Hong Chung, Sangrak Bae, Tae-Hyoung Kim
Urogenit Tract Infect 2021;16(2):49-54. Published online August 31, 2021
Purpose: This study examined the characteristics, current treatment trends, and outcomes of patients with emphysematous pyelonephritis (EPN) in Korea. Materials andMethods: Two hundred and seventeen patients diagnosed with EPN were evaluated using abdominal computed tomography in 2011-2021 at 15 institutes in Korea. The patients’ demographic and clinical characteristics, treatment modalities, and treatment outcomes were analyzed. The total study period was divided arbitrarily into groups A (2011-2014), B (2015-2017), and C (2018-2021) to analyze the trends in the EPN treatment. Results: The mean age of the patients was 65.1 years; there were more female patients (74.2%) than male patients. The overall mortality rate was 10.6%. Ninety-five (43.8%), 98 (45.2%), and 24 (11.0%) patients were treated with medical, minimally invasive, and surgical management, respectively; the corresponding mortality rates were 13.7%, 6.1%, and 16.7%. There was no significant change in the proportion of patients treated with medical management over time (group A=46.5%, group B=47.0%, and group C=38.8%). The proportion of patients treated with minimally invasive management gradually increased over time (group A=35.2%; group B=43.9%; group C=55.0%), while those who underwent surgical management decreased gradually over time (group A=18.3%, group B=9.1%, and group C=6.3%). No differences in mortality rates were observed between the groups. Conclusions: EPN with medical and minimally invasive management had a relatively high treatment success rate, which increased gradually, while surgical management decreased gradually over time in Korea. The mortality rate was relatively lower than that reported in studies published before the 2010s.